## Martina Olivero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5657495/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth Journal of Cell Biology, 1992, 119, 629-641.	2.3	1,282
2	Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 2000, 19, 1547-1555.	2.6	314
3	Overexpression of theMET/HGF receptor in ovarian cancer. International Journal of Cancer, 1994, 58, 658-662.	2.3	208
4	Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. British Journal of Cancer, 1996, 74, 1862-1868.	2.9	191
5	Overexpression of the met/HGF receptor in renal cell carcinomas. , 1996, 69, 212-217.		127
6	MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Research, 2006, 66, 4750-4757.	0.4	123
7	Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression. Cancer Research, 2004, 64, 5154-5161.	0.4	96
8	Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Research, 2002, 62, 7025-30.	0.4	92
9	Novel mutation in the ATP-binding site of theMET oncogene tyrosine kinase in a HPRCC family. , 1999, 82, 640-643.		82
10	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. Cancer Research, 2007, 67, 7675-7685.	0.4	81
11	Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients. Scientific Reports, 2018, 8, 2378.	1.6	74
12	Extracellular Vesicles Mediate Mesenchymal Stromal Cell-Dependent Regulation of B Cell PI3K-AKT Signaling Pathway and Actin Cytoskeleton. Frontiers in Immunology, 2019, 10, 446.	2.2	73
13	Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocrine Pathology, 2000, 11, 19-30.	5.2	72
14	Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Research, 2005, 65, 907-12.	0.4	72
15	Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. Journal of Endocrinological Investigation, 1995, 18, 134-139.	1.8	63
16	Staging of head and neck squamous cell carcinoma using theMET oncogene product as marker of tumor cells in lymph node metastases. International Journal of Cancer, 2000, 89, 286-292.	2.3	59
17	Molecular Analysis of the GNAS1 Gene for the Correct Diagnosis of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism. Pediatric Research, 2003, 53, 749-755.	1.1	57
18	Sparsely-connected autoencoder (SCA) for single cell RNAseq data mining. Npj Systems Biology and Applications, 2021, 7, 1.	1.4	53

MARTINA OLIVERO

#	Article	IF	CITATIONS
19	Reproducible bioinformatics project: a community for reproducible bioinformatics analysis pipelines. BMC Bioinformatics, 2018, 19, 349.	1.2	49
20	MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. Journal of Cellular Physiology, 2001, 189, 285-290.	2.0	46
21	HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. International Journal of Cancer, 2014, 134, 1289-1299.	2.3	44
22	Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 2737.	1.8	44
23	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. Gynecologic Oncology, 2015, 138, 627-633.	0.6	43
24	Detection ofMET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. European Archives of Oto-Rhino-Laryngology, 1997, 254, S138-S143.	0.8	42
25	A Mouse Model of Pulmonary Metastasis from Spontaneous Osteosarcoma Monitored In Vivo by Luciferase Imaging. PLoS ONE, 2008, 3, e1828.	1.1	38
26	Control of invasive growth by the HGF receptor family. Journal of Cellular Physiology, 1997, 173, 183-186.	2.0	35
27	<i>met</i> oncogene activation qualifies spontaneous canine osteosarcoma as a suitable preâ€elinical model of human osteosarcoma. Journal of Pathology, 2009, 218, 399-408.	2.1	34
28	The cellular apoptosis susceptibility <i>CAS/CSE1L</i> gene protects ovarian cancer cells from death by suppressing RASSF1C. FASEB Journal, 2012, 26, 2446-2456.	0.2	34
29	Heatâ€shock protein 27 (HSP27, HSPB1) is upâ€regulated by MET kinase inhibitors and confers resistance to METâ€targeted therapy. FASEB Journal, 2014, 28, 4055-4067.	0.2	34
30	Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. Molecular Oncology, 2017, 11, 599-611.	2.1	32
31	Deletion in a (T)8 microsatellite abrogates expression regulation by 3'-UTR. Nucleic Acids Research, 2003, 31, 6561-6569.	6.5	30
32	The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo. Clinical Cancer Research, 2007, 13, 2191-2198.	3.2	29
33	Cells Lacking the Fumarase Tumor Suppressor Are Protected from Apoptosis through a Hypoxia-Inducible Factor-Independent, AMPK-Dependent Mechanism. Molecular and Cellular Biology, 2012, 32, 3081-3094.	1.1	29
34	IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. European Journal of Cancer, 2013, 49, 964-973.	1.3	29
35	Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Molecular Cancer Therapeutics, 2006, 5, 1126-1135.	1.9	27
36	The <i>MET</i> oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. Journal of Bone and Mineral Research, 2012, 27, 1322-1334.	3.1	27

MARTINA OLIVERO

#	Article	IF	CITATIONS
37	rCASC: reproducible classification analysis of single-cell sequencing data. GigaScience, 2019, 8, .	3.3	26
38	PIM2 Kinase Is Induced by Cisplatin in Ovarian Cancer Cells and Limits Drug Efficacy. Journal of Proteome Research, 2014, 13, 4970-4982.	1.8	22
39	RNA-Seq profiling in peripheral blood mononuclear cells of amyotrophic lateral sclerosis patients and controls. Scientific Data, 2019, 6, 190006.	2.4	22
40	AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells. Experimental Cell Research, 2013, 319, 2627-2636.	1.2	21
41	A cancerâ€predisposing "hot spot―mutation of the fumarase gene creates a dominant negative protein. International Journal of Cancer, 2008, 122, 947-951.	2.3	20
42	The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase. Oncotarget, 2014, 5, 5992-6002.	0.8	17
43	The expression ofMet/hepatocyte growth factor receptor gene in giant cell tumors of bone and other benign musculoskeletal tumors. Journal of Cellular Physiology, 2000, 184, 191-196.	2.0	15
44	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget, 2016, 7, 26181-26191.	0.8	15
45	Amplification of repeat-containing transcribed sequences (ARTS): a transcriptome fingerprinting strategy to detect functionally relevant microsatellite mutations in cancer. Nucleic Acids Research, 2003, 31, 33e-33.	6.5	14
46	Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. International Journal of Molecular Sciences, 2022, 23, 833.	1.8	14
47	Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism. Oncotarget, 2016, 7, 712-728.	0.8	13
48	Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB Journal, 2010, 24, 2680-2688.	0.2	12
49	The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs. European Journal of Cancer, 2016, 60, 59-68.	1.3	10
50	Circulating Extracellular Vesicles Contain Liver-Derived RNA Species as Indicators of Severe Cholestasis-Induced Early Liver Fibrosis in Mice. Antioxidants and Redox Signaling, 2022, 36, 480-504.	2.5	9
51	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. Cells, 2020, 9, 442.	1.8	7
52	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Advances, 2021, 5, 5239-5257.	2.5	7
53	Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. Scientific Reports, 2021, 11, 1563.	1.6	6
54	Factor VIII as a potential player in cancer pathophysiology. Journal of Thrombosis and Haemostasis, 2022, 20, 648-660.	1.9	4

#	Article	IF	CITATIONS
55	Heat Shock Protein 27 (HSP27, HSPB1) Is Up-Regulated by Targeted Agents and Confers Resistance to Both Targeted Drugs and Chemotherapeutics. Heat Shock Proteins, 2015, , 17-25.	0.2	1